Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma

Glioblastoma (GBM) is an ideal candidate disease for signal transduction targeted therapy because the majority of these tumors harbor genetic alterations that result in aberrant activation of growth factor signaling pathways. Loss of heterozygosity of chromosome 10, mutations in the tumor suppressor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Koul, Dimpy, Wang, Shuzhen, Wu, Shaofang, Saito, Norihiko, Zheng, Siyuan, Gao, Feng, Kaul, Isha, Setoguchi, Masaki, Nakayama, Kiyoshi, Koyama, Kumiko, Shiose, Yoshinobu, Sulman, Erik P., Hirota, Yasuhide, Yung, W.K. Alfred
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400620/
https://ncbi.nlm.nih.gov/pubmed/28423515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15566
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados